Should I buy or sell Biofrontera stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BFRI shares. View BFRI analyst ratings or view top-rated stocks .

What is Biofrontera's stock price target for 2024?

1 brokerages have issued twelve-month target prices for Biofrontera's stock. Their BFRI share price targets range from $18.00 to $18.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 955.7% from the stock's current price. View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts .

How have BFRI shares performed in 2024?

Biofrontera's stock was trading at $2.77 at the beginning of 2024. Since then, BFRI stock has decreased by 38.4% and is now trading at $1.7050. View the best growth stocks for 2024 here .

Are investors shorting Biofrontera?

Biofrontera saw a decrease in short interest in March. As of March 31st, there was short interest totaling 34,800 shares, a decrease of 58.7% from the March 15th total of 84,200 shares. Based on an average daily volume of 755,900 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.0% of the shares of the company are short sold. View Biofrontera's Short Interest .

When is Biofrontera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BFRI earnings forecast .

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) released its earnings results on Friday, March, 15th. The company reported ($2.33) EPS for the quarter. The business earned $10.60 million during the quarter. Biofrontera had a negative net margin of 59.09% and a negative trailing twelve-month return on equity of 344.98%.

When did Biofrontera's stock split?

Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera issued an update on its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$34.3 million, compared to the consensus revenue estimate of $35.9 million.

When did Biofrontera IPO?

Biofrontera (BFRI) raised $19 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO.

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BFRI

Biofrontera (BFRI) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free BFRI Stock Alerts

$1.70

+0.04 (+2.10%)

(As of 01:46 PM ET)

Compare

Today's Range: $1.67
▼
$1.79
50-Day Range: $0.68
▼
$2.38
52-Week Range: $0.61
▼
$13.42

Volume: 55,298 shs
Average Volume: 669,067 shs
Market Capitalization: $8.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Get Biofrontera alerts:

Biofrontera MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 955.7% Upside
$18.00 Price Target
Short Interest: Healthy
0.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.01) to ($0.19) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Biofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biofrontera has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.95% of the float of Biofrontera has been sold short.
Short Interest Ratio / Days to Cover
Biofrontera has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biofrontera has recently decreased by 58.67%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Biofrontera does not currently pay a dividend.
Dividend Growth
Biofrontera does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BFRI.

1.1

News and Social Media Coverage

Search Interest
4 people have searched for BFRI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
5 people have added Biofrontera to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biofrontera insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.69% of the stock of Biofrontera is held by insiders.
Percentage Held by Institutions
Only 10.08% of the stock of Biofrontera is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Biofrontera are expected to grow in the coming year, from ($4.01) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biofrontera is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biofrontera is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biofrontera has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Biofrontera Stock (NASDAQ:BFRI)

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BFRI Stock News Headlines

March 24, 2024 | investorplace.com

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

March 20, 2024 | seekingalpha.com

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

March 19, 2024 | finance.yahoo.com

Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript

March 18, 2024 | msn.com

Biofrontera GAAP EPS of $1.65 beats by $2.79, revenue of $10.6M misses by $1.21M

February 20, 2024 | msn.com

Biofrontera stock soars on announcing private placement of up to $16M

February 20, 2024 | finance.yahoo.com

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

January 31, 2024 | finance.yahoo.com

Biofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

January 11, 2024 | msn.com

Biofrontera sees 19% growth in prelim FY 2023 revenue

November 22, 2023 | finance.yahoo.com

Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

November 11, 2023 | finance.yahoo.com

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript

November 11, 2023 | finance.yahoo.com

Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% Plummet

November 9, 2023 | finance.yahoo.com

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 9, 2023 | finance.yahoo.com

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know

November 3, 2023 | finance.yahoo.com

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

October 31, 2023 | finance.yahoo.com

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

October 21, 2023 | ca.finance.yahoo.com

Biofrontera Inc. (BFRI) Stock Price, News, Quote & History - Yahoo Finance

October 10, 2023 | finanznachrichten.de

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz

October 10, 2023 | finance.yahoo.com

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

October 5, 2023 | finance.yahoo.com

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

September 18, 2023 | msn.com

All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy

August 28, 2023 | finanznachrichten.de

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz

August 28, 2023 | finance.yahoo.com

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

August 10, 2023 | benzinga.com

Earnings Outlook For Biofrontera

August 4, 2023 | finance.yahoo.com

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

July 13, 2023 | finance.yahoo.com

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

See More Headlines

Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BFRI
CUSIP: N/A
CIK: 1858685
Web: www.biofrontera-us.com
Phone: 781-245-1325
Fax: N/A
Employees: 83
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.00
High Stock Price Target: $18.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +977.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($15.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,130,000.00
Net Margins: -59.09%
Pretax Margin: -59.04%
Return on Equity: -344.98%
Return on Assets: -72.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.28
Quick Ratio: 0.67

Sales & Book Value

Annual Sales: $34.07 million
Price / Sales: 0.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.16 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 5,090,000
Free Float: 5,054,000
Market Cap: $8.50 million
Optionable: No Data
Beta: 0.83

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Hermann Luebbert Ph.D. (Age 68)
CEO, President & Executive Chairman
Comp: $733.23k
Mr. Eugene Frederick Leffler III (Age 39)
Chief Financial Officer
Comp: $378.58k
Ms. Erica F. Gates CPA
M.B.A., Senior Director of Finance & Principal Accounting Officer
Mr. Jon Lyons M.B.A.
Ph.D., Vice President of Scientific & Medical Affairs
Ms. Alycia Torres
Vice President of Administration
Mr. Daniel Hakansson J.D.
General Counsel & Head of Compliance
Ms. Samantha Widdicombe
Senior Director of Strategic Accounts & Communications
Mr. Mark Baldyga
Vice President of Sales & Marketing

Key Competitors

View All Competitors

BFRI Stock Analysis - Frequently Asked Questions

Should I buy or sell Biofrontera stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings or view top-rated stocks.
What is Biofrontera's stock price target for 2024?: 1 brokerages have issued twelve-month target prices for Biofrontera's stock. Their BFRI share price targets range from $18.00 to $18.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 955.7% from the stock's current price.
View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts.
How have BFRI shares performed in 2024?: Biofrontera's stock was trading at $2.77 at the beginning of 2024. Since then, BFRI stock has decreased by 38.4% and is now trading at $1.7050.
View the best growth stocks for 2024 here.
Are investors shorting Biofrontera?: Biofrontera saw a decrease in short interest in March. As of March 31st, there was short interest totaling 34,800 shares, a decrease of 58.7% from the March 15th total of 84,200 shares. Based on an average daily volume of 755,900 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.0% of the shares of the company are short sold.
View Biofrontera's Short Interest.
When is Biofrontera's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BFRI earnings forecast.
How were Biofrontera's earnings last quarter?: Biofrontera Inc. (NASDAQ:BFRI) released its earnings results on Friday, March, 15th. The company reported ($2.33) EPS for the quarter. The business earned $10.60 million during the quarter. Biofrontera had a negative net margin of 59.09% and a negative trailing twelve-month return on equity of 344.98%.

When did Biofrontera's stock split?: Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What guidance has Biofrontera issued on next quarter's earnings?: Biofrontera issued an update on its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$34.3 million, compared to the consensus revenue estimate of $35.9 million.
When did Biofrontera IPO?: Biofrontera (BFRI) raised $19 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO.
How do I buy shares of Biofrontera?: Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BFRI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial